CVS Health shareholders approve 2026 incentive plan; all 13 directors elected
At its May 14, 2026 annual meeting, CVS Health stockholders approved a 2026 Incentive Compensation Plan that replaces the expiring 2017 plan, and elected all 13 director nominees to one-year terms. Stockholders also ratified Ernst & Young LLP as auditor for 2026 and approved the advisory say-on-pay proposal, while a stockholder proposal to lower the threshold for acting by written consent was not approved.
Key points
- The 2026 Incentive Compensation Plan applies to awards granted after May 14, 2026; the vote was 1,006,709,390 for and 28,851,289 against.
- The stockholder proposal on acting by written consent received 417,969,177 for and 617,361,014 against, and was not approved.
- Shares present at the meeting totaled 1,142,802,406, constituting a quorum.
- The advisory say-on-pay proposal was approved with 976,252,194 for and 59,088,923 against.
The filing
Written by AI on Nov 8, 2026, 1:21 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 18, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.